J
John Emswiler
Researcher at Bristol-Myers Squibb
Publications - 8
Citations - 1941
John Emswiler is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Binding site & Ligand (biochemistry). The author has an hindex of 8, co-authored 8 publications receiving 1847 citations. Previous affiliations of John Emswiler include University of Washington.
Papers
More filters
Journal ArticleDOI
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.
Walter W. Shuford,Kerry Klussman,Douglas D. Tritchler,Deryk T. Loo,Jan N. Chalupny,Siadak Anthony W,T. Joseph Brown,John Emswiler,Hong Raecho,Christian P. Larsen,Thomas C. Pearson,Jeffrey A. Ledbetter,Alejandro Aruffo,Robert S. Mittler +13 more
TL;DR: It is demonstrated that CD8+ T cells when compared with CD4+ T Cells are preferentially responsive to both early activation events and proliferative signals provided via the TCR and 4-1BB.
Journal ArticleDOI
Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties
Christian P. Larsen,Thomas C. Pearson,Andrew B. Adams,Paul L. Tso,Nozomu Shirasugi,Elizabeth Strobert,Daniel G. Anderson,Shannon R. Cowan,Karen Price,Naemura Joseph R,John Emswiler,Jo Anne L. Greene,Lori A. Turk,Jürgen Bajorath,Robert M. Townsend,David Hagerty,Peter S. Linsley,Robert J. Peach +17 more
TL;DR: An attempt to increase the biologic potency of the parent molecule a novel, modified version of CTLA4‐Ig, LEA29Y (belatacept), was constructed, resulting in a 10‐fold increase in potency in vitro and significant prolongation of renal allograft survival in a pre‐clinical primate model.
Journal ArticleDOI
Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions
JoAnne L. Greene,Gina Leytze,John Emswiler,Robert J. Peach,Jürgen Bajorath,Wesley L. Cosand,Peter S. Linsley +6 more
TL;DR: Covalent receptor dimerization and ligand oligomerization are two key features of the CD28/CTLA-4/CD80/CD86 receptor system that control ligand binding and may regulate signal transduction by controlling the duration of receptor occupancy.
Journal ArticleDOI
Identification of amino acid residues important for ligand binding to fas
Gary C. Starling,Jürgen Bajorath,John Emswiler,Jeffrey A. Ledbetter,Alejandro Aruffo,Peter A. Kiener +5 more
TL;DR: The binding of FasL involves residues in two domains that correspond to positions critical for ligand binding in other family members but are conserved between murine and human Fas.
Journal Article
In Vitro and In Vivo Activities of a Doxorubicin Prodrug in Combination with Monoclonal Antibody β-Lactamase Conjugates
Håkan P. Svensson,Vivekananda M. Vrudhula,John Emswiler,John F. MacMaster,Wesley L. Cosand,Peter D. Senter,Philip M. Wallace +6 more
TL;DR: In vivo toxicity and pharmacokinetics studies in athymic female nu/nu mice revealed that C-Dox was at least 7-fold less toxic than Dox (on a molar basis), despite the fact that a ≥320-fold greater area-under-the-curve of C- Dox compared to Dox was obtained 0–2 h after administration of the two agents.